Teva Gets FDA Approval for ArmonAir Digihaler Inhalation Powder
February 24 2020 - 9:13AM
Dow Jones News
By Michael Dabaie
Teva Respiratory LLC, an affiliate of Teva Pharmaceutical
Industries Ltd., said the U.S. Food and Drug Administration has
approved ArmonAir Digihaler Inhalation Powder.
The inhaled corticosteroid is delivered by Teva's Digihaler
device, which contains built-in sensors and connects to a companion
mobile application that provides information on inhaler use to
people with asthma.
ArmonAir Digihaler is indicated for the maintenance treatment of
asthma in patients 12 years and older, Teva said.
The approval was based on the review of the supplemental new
drug application submitted by Teva to the FDA.
Teva ADRs were down 4% premarket to $12.65.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 24, 2020 08:58 ET (13:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024
